Find latest Non-Small Cell Lung Cancer videos
·
600+ videos
Video Player is loading.
10 seconds
Playback speed
ELCC 2025 Summary: EGFRm and HER2-Mutated/Overexpressing Advanced NSCLC Updates From Recent Trials
By
COR2ED The Heart of Medical Education
FEATURING
Nicolas Girard
By
COR2ED The Heart of Medical Education
FEATURING
Nicolas Girard
In this conference highlights video, Prof. Nicolas Girard shares his perspectives on the latest data for oncogene-addicted non-small cell lung cancer (NSCLC) from ELCC 2025.
Prof. Girard reviews the following clinical trials:
• Phase I/II SOHO-01 study of BAY 2927088 in patients with previously treated HER2-mutant NSCLC: Safety and efficacy results from 2 expansion cohorts.
Girard N, et al. Abstract 3O, ELCC 2025
• Amivantamab Plus Lazertinib vs Osimertinib in First-line EGFR-mutant Advanced NSCLC: Final Overall Survival from the Phase 3 MARIPOSA Study.
Chih-Hsin Yang J, et al. Abstract 4O, ELCC 2025
• Osimertinib + datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC whose disease progressed on first-line osimertinib:
ORCHARD. Le X, et al. Abstract 1O, ELCC 2025
• Phase 1b open-label study of trastuzumab deruxtecan + rilvegostomig _ carboplatin as first-line treatment for metastatic HER2-overexpressing NSCLC: DESTINY-Lung03 (DL-03) Part 4
Planchard D, et al. 132TiP, ELCC 2025
Follow LUNG CONNECT on:
X
LinkedIn
This content is intended for healthcare professionals only.
The medical experts in this video are expressing their own views and not those of COR2ED, Supporters or their institution. This video is supported by an Independent Education Grant from Bayer.
This video is developed by cor2ed.com
Published April 2024
Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.
Prof. Girard reviews the following clinical trials:
• Phase I/II SOHO-01 study of BAY 2927088 in patients with previously treated HER2-mutant NSCLC: Safety and efficacy results from 2 expansion cohorts.
Girard N, et al. Abstract 3O, ELCC 2025
• Amivantamab Plus Lazertinib vs Osimertinib in First-line EGFR-mutant Advanced NSCLC: Final Overall Survival from the Phase 3 MARIPOSA Study.
Chih-Hsin Yang J, et al. Abstract 4O, ELCC 2025
• Osimertinib + datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC whose disease progressed on first-line osimertinib:
ORCHARD. Le X, et al. Abstract 1O, ELCC 2025
• Phase 1b open-label study of trastuzumab deruxtecan + rilvegostomig _ carboplatin as first-line treatment for metastatic HER2-overexpressing NSCLC: DESTINY-Lung03 (DL-03) Part 4
Planchard D, et al. 132TiP, ELCC 2025
Follow LUNG CONNECT on:
X
This content is intended for healthcare professionals only.
The medical experts in this video are expressing their own views and not those of COR2ED, Supporters or their institution. This video is supported by an Independent Education Grant from Bayer.
This video is developed by cor2ed.com
Published April 2024
Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.
Comments 0
Login to view comments.
Click here to Login
